Company News

bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.

For 20 years, bioMérieux and the Hospices Civils de Lyon (HCL) have been collaborating in an innovative public/private research partnership. Joined in 2016 by Claude Bernard Lyon 1 University, the three institutions are working to figure out the mechanisms of immunity in order to develop diagnostic tests.

bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the incorporation of the company’s innovative GENE-UP^® QUANT Salmonella assay into the methodology used by the USDA Food Safety Inspection Service regional laboratories. 

The 3P® ENTERPRISE solution has been developed by bioMérieux to fully address the daily industrial challenges of Environmental Monitoring (EM). Developed and validated, in collaboration with major global pharmaceutical companies, 3P® ENTERPRISE provides an end-to-end solution that fully digitalizes and automates the EM process.

The French bioproduction sector – in the form of a top-tier industrial consortium led by bioMérieux, Novasep, Sanofi and Servier – announced the launch of immerscio.bio at the France Bioproduction 2022 Congress on April 7 and 8. immerscio.bio will cover the entire bioproduction chain, employing a range of innovative digital solutions to promote the understanding of processes and the ownership of professional practices.